Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1B Study to Evaluate the Safety and Induction of Immune Response of CRS-207 in Combination With Pemetrexed and Cisplatin as Front-line Therapy in Adults With Malignant Pleural Mesothelioma

Trial Profile

A Phase 1B Study to Evaluate the Safety and Induction of Immune Response of CRS-207 in Combination With Pemetrexed and Cisplatin as Front-line Therapy in Adults With Malignant Pleural Mesothelioma

Discontinued
Phase of Trial: Phase I

Latest Information Update: 01 Jul 2019

At a glance

  • Drugs CRS 207 (Primary) ; Cisplatin; Cyclophosphamide; Pemetrexed
  • Indications Mesothelioma
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Aduro BioTech
  • Most Recent Events

    • 01 Jul 2019 Results published in the Clinical Cancer Research
    • 08 Jan 2019 Planned End Date changed from 1 Dec 2018 to 1 Jun 2019.
    • 08 Jan 2019 Planned primary completion date changed from 1 Dec 2018 to 1 Jun 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top